872511-32-5

Basic information

• Product Name: Benzene, 2,4-dichloro-3-isocyanato-1,5-dimethoxy-
• CAS NO: 872511-32-5
• Molecular Formula: C9H7Cl2NO3
• Molecular Weight: 248.065
• Mol File: 872511-32-5.mol
• Article Data: 11

Chemical Properties

• CAS DataBase Reference: Benzene, 2,4-dichloro-3-isocyanato-1,5-dimethoxy-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzene, 2,4-dichloro-3-isocyanato-1,5-dimethoxy-(872511-32-5)
• EPA Substance Registry System: Benzene, 2,4-dichloro-3-isocyanato-1,5-dimethoxy-(872511-32-5)

Safety Data

• Hazardous Substances Data: 872511-32-5(Hazardous Substances Data)

Usage

General Description

Benzene, 2,4-dichloro-3-isocyanato-1,5-dimethoxy- is a chemical compound with the molecular formula C10H8Cl2N2O4. It is a derivative of benzene and isocyanate, with two chlorine atoms attached to the benzene ring and two methoxy groups attached to the isocyanate group. Benzene, 2,4-dichloro-3-isocyanato-1,5-dimethoxy- is primarily used in the production of various polyurethane foams, adhesives, and coatings. It is considered hazardous and should be handled with caution due to its potential health effects, including respiratory and skin irritation, as well as its environmental impact.

Upstream product

• 872509-56-3 2,6-dichloro-3,5-dimethoxy-phenylamine 
• 32315-10-9 bis(trichloromethyl) carbonate 
• 10272-07-8 3.5-dimethoxyaniline 
• 79257-61-7 N-(3,5-dimethoxy-phenyl)-acetamide 
• 943189-21-7 N-(2,6-dichloro-3,5-dimethoxy-phenyl)-acetamide 
• 75-44-5 phosgene 

Relevant articles and documents

Discovery of a Potent Degrader for Fibroblast Growth Factor Receptor 1/2

Aberrant activation of FGFR signaling occurs in many cancers, and ATP-competitive FGFR inhibitors have received regulatory approval. Despite demonstrating clinical efficacy, these inhibitors exhibit dose-limiting toxicity, potentially due to a lack of selectivity amongst the FGFR family and are poorly tolerated. Here, we report the discovery and characterization of DGY-09-192, a bivalent degrader that couples the pan-FGFR inhibitor BGJ398 to a CRL2VHL E3 ligase recruiting ligand, which preferentially induces FGFR1&2 degradation while largely sparing FGFR3&4. DGY-09-192 exhibited two-digit nanomolar DC50s for both wildtype FGFR2 and several FGFR2-fusions, resulting in degradation-dependent antiproliferative activity in representative gastric cancer and cholangiocarcinoma cells. Importantly, DGY-09-192 induced degradation of a clinically relevant FGFR2 fusion protein in a xenograft model. Taken together, we demonstrate that DGY-09-192 has potential as a prototype FGFR degrader.

FGFR4 inhibitor and application thereof

The invention belongs to the field of medical chemistry, and particularly relates to a novel FGFR4 inhibitor, a medicine composition comprising the inhibitor and a use of the inhibitor or medicine composition as a cancer curative drug.

A model used for fibroblast growth factor receptor inhibitors and use thereof (by machine translation)

The invention belongs to the field of medical technology, in particular of formula (I) indicated by the fibroblast growth factor receptor 4 (FGFR4) irreversible inhibitors, their pharmaceutically acceptable salt, compound solvent, polymorphs and tautomeri